These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 28221216)

  • 1. L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer.
    Abdel Azim S; Sprung S; Mutz-Dehbalaie I; Fessler S; Zeimet AG; Marth C
    Int J Gynecol Pathol; 2017 Jul; 36(4):356-363. PubMed ID: 28221216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Soovares P; Pasanen A; Bützow R; Lassus H
    Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
    Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
    Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
    Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
    Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
    Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
    Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
    Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.
    Zeimet AG; Reimer D; Huszar M; Winterhoff B; Puistola U; Azim SA; Müller-Holzner E; Ben-Arie A; van Kempen LC; Petru E; Jahn S; Geels YP; Massuger LF; Amant F; Polterauer S; Lappi-Blanco E; Bulten J; Meuter A; Tanouye S; Oppelt P; Stroh-Weigert M; Reinthaller A; Mariani A; Hackl W; Netzer M; Schirmer U; Vergote I; Altevogt P; Marth C; Fogel M
    J Natl Cancer Inst; 2013 Aug; 105(15):1142-50. PubMed ID: 23781004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
    Smogeli E; Davidson B; Cvancarova M; Holth A; Katz B; Risberg B; Kristensen G; Lindemann K
    BMC Cancer; 2016 Aug; 16():596. PubMed ID: 27488577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
    van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
    Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.
    Klat J; Mladenka A; Dvorackova J; Bajsova S; Simetka O
    Anticancer Res; 2019 Jan; 39(1):421-424. PubMed ID: 30591489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker.
    Pasanen A; Loukovaara M; Tuomi T; Bützow R
    Int J Gynecol Cancer; 2017 Sep; 27(7):1318-1324. PubMed ID: 29059097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas.
    Huszar M; Pfeifer M; Schirmer U; Kiefel H; Konecny GE; Ben-Arie A; Edler L; Münch M; Müller-Holzner E; Jerabek-Klestil S; Abdel-Azim S; Marth C; Zeimet AG; Altevogt P; Fogel M
    J Pathol; 2010 Apr; 220(5):551-61. PubMed ID: 20077528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L1CAM: amending the "low-risk" category in endometrial carcinoma.
    Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA).
    Dellinger TH; Smith DD; Ouyang C; Warden CD; Williams JC; Han ES
    Gynecol Oncol; 2016 May; 141(2):336-340. PubMed ID: 26861585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group.
    Yoon H; Suh DH; Kim K; No JH; Kim YB; Kim H
    Gynecol Oncol; 2024 May; 184():132-138. PubMed ID: 38309030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
    Visser NCM; van der Putten LJM; van Egerschot A; Van de Vijver KK; Santacana M; Bronsert P; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Krakstad C; Tangen IL; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Hausnerova J; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Trovik J; Amant F; Massuger LFAG; Bulten J; Pijnenborg JMA
    Hum Pathol; 2019 Jul; 89():90-98. PubMed ID: 31054899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
    Bosse T; Nout RA; Stelloo E; Dreef E; Nijman HW; Jürgenliemk-Schulz IM; Jobsen JJ; Creutzberg CL; Smit VT
    Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
    Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
    Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesonephric-like Adenocarcinoma of the Uterine Corpus: Clinicopathological and Prognostic Significance of L1 Cell Adhesion Molecule (L1CAM) Over-expression.
    Park S; Cho Y; Kim HS
    Anticancer Res; 2023 Oct; 43(10):4559-4571. PubMed ID: 37772557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
    Nakayama K; Rahman MT; Rahman M; Nakamura K; Ishikawa M; Katagiri H; Sato E; Ishibashi T; Iida K; Ishikawa N; Kyo S
    Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.